Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Sell

Analyst Rating

Neutral

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

AMCON Distributing Co. (DIT)

Wholesale-groceries, General Line

https://www.amcon.com

Amcon Distributing Co is engaged in the wholesale and retail distribution of consumer products such as cigarettes, tobacco, confectionery, health food, and others. It operates in two segments: Wholesale distribution segment distributing consumer products to the retail outlets including convenience stores, grocery stores, liquor stores, drug stores, and tobacco shops in the Central, Rocky Mountain, and Southern regions of the United States; and the Retail health food segment is a specialty retailer of natural/organic groceries and dietary supplements throughout the Midwest and Florida. The company earns a majority of the revenue from the Wholesale distribution segment.

7405 IRVINGTON ROAD, POST OFFICE BOX 641940 (68164-7940)
OMAHA, NE

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

08/04/1995

Market Cap

87,620,318

Shares Outstanding

630,000

Weighted SO

630,362

Total Employees

N/A

Upcoming Earnings

N/A

Beta

0.5600

Last Div

0.7200

Range

119.34-224.47

Chg

-2.0000

Avg Vol

387

Mkt Cap

87620318

Exch

AMEX

Country

US

Phone

402 331 3727

DCF Diff

-74.9797

DCF

212.9797

Div Yield

0.0072

P/S

0.0330

EV Multiple

9.3942

P/FV

0.7586

Div Yield %

0.7194

P/E

13.7721

PEG

67.4580

Payout

0.1037

Current Ratio

3.0510

Quick Ratio

1.1518

Cash Ratio

0.0085

DSO

11.0988

DIO

23.6586

Op Cycle

34.7573

DPO

6.8056

CCC

27.9518

Gross Margin

0.0665

Op Margin

0.0081

Pretax Margin

0.0037

Net Margin

0.0023

Eff Tax Rate

0.3901

ROA

0.0151

ROE

0.0565

ROCE

0.0684

NI/EBT

0.6099

EBT/EBIT

0.4593

EBIT/Rev

0.0081

Debt Ratio

0.4664

D/E

1.6992

LT Debt/Cap

0.6139

Total Debt/Cap

0.6295

Int Coverage

2.2144

CF/Debt

0.1985

Equity Multi

3.6429

Rec Turnover

32.8865

Pay Turnover

53.6325

Inv Turnover

15.4278

FA Turnover

20.6465

Asset Turnover

6.6330

OCF/Share

61.7922

FCF/Share

25.8104

Cash/Share

1.1986

OCF/Sales

0.0140

FCF/OCF

0.4177

CF Coverage

0.1985

ST Coverage

3.0912

CapEx Coverage

1.7173

Div&CapEx Cov

1.6688

P/BV

0.7586

P/B

0.7586

P/S

0.0330

P/E

13.7721

P/FCF

5.6564

P/OCF

2.2495

P/CF

2.2495

PEG

67.4580

P/S

0.0330

EV Multiple

9.3942

P/FV

0.7586

DPS

1.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 12, 06:01 Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June The Motley Fool Jan 21, 09:37 Could Editas Medicine Become the Next CRISPR Therapeutics? The Motley Fool Jan 21, 09:37 Could Editas Medicine Become the Next CRISPR Therapeutics? The Motley Fool Jan 21, 09:37 Could Editas Medicine Become the Next CRISPR Therapeutics? The Motley Fool Jan 15, 05:19 Down 88%, Could Editas Medicine Be a Good Investment Now? The Motley Fool Jan 08, 07:45 Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics The Motley Fool Dec 23, 08:02 Editas Just Caught a Break Thanks to Vertex Pharmaceuticals The Motley Fool Dec 23, 08:02 Editas Just Caught a Break Thanks to Vertex Pharmaceuticals MarketWatch Dec 13, 12:03 Vertex's stock heads for all-time high as non-opioid painkiller shows promise MarketWatch Dec 09, 07:47 Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment MarketWatch Dec 09, 07:47 Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment MarketWatch Dec 09, 07:47 Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment MarketWatch Dec 08, 12:03 Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatment The Motley Fool Dec 04, 08:30 You Don't Have to Pick a Winner in Gene-Editing. Do This Instead. The Motley Fool Nov 20, 05:36 2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street GlobeNewswire Inc. Nov 03, 07:00 Editas Medicine Announces Third Quarter 2023 Results and Business Updates GlobeNewswire Inc. Nov 02, 09:12 Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar The Motley Fool Oct 30, 08:30 Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient Investing.com Oct 29, 09:46 Pinterest Primed for Rich Ad Spend; Adobe a Powerhouse: Street Calls of the Week Investing.com Oct 29, 09:46 Pinterest Primed for Rich Ad Spend; Adobe a Powerhouse: Street Calls of the Week

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.18 05/02/2024 04/23/2024 05/03/2024 05/13/2024
0.18 02/01/2024 01/23/2024 02/02/2024 02/12/2024
0.28 01/05/2024 12/27/2023 01/08/2024 01/17/2024
0.18 11/03/2023 10/24/2023 11/06/2023 11/17/2023
0.18 08/03/2023 07/25/2023 08/04/2023 08/17/2023
0.18 05/04/2023 04/25/2023 05/05/2023 05/18/2023
0.18 02/02/2023 01/25/2023 02/03/2023 02/16/2023
5.00 12/30/2022 12/22/2022 01/03/2023 01/13/2023
0.18 11/04/2022 10/25/2022 11/07/2022 11/30/2022
0.18 08/04/2022 07/26/2022 08/05/2022 08/29/2022
0.18 05/05/2022 04/26/2022 05/06/2022 05/31/2022
0.18 02/03/2022 01/25/2022 02/04/2022 03/01/2022
5.00 12/22/2021 12/10/2021 12/23/2021 12/30/2021
0.18 11/04/2021 10/26/2021 11/05/2021 11/30/2021
0.18 08/05/2021 07/27/2021 08/06/2021 08/30/2021
0.18 05/06/2021 04/27/2021 05/07/2021 06/01/2021
0.18 02/04/2021 01/26/2021 02/05/2021 03/02/2021
5.00 12/31/2020 12/22/2020 01/04/2021 01/12/2021
0.18 11/05/2020 10/27/2020 11/06/2020 12/01/2020
0.18 07/30/2020 07/21/2020 07/31/2020 08/24/2020
0.18 04/30/2020 04/21/2020 05/01/2020 05/26/2020
0.18 02/07/2020 01/28/2020 02/10/2020 03/04/2020
0.28 01/03/2020 12/23/2019 01/06/2020 01/28/2020
0.18 11/05/2019 10/22/2019 11/06/2019 11/27/2019
0.18 08/02/2019 07/23/2019 08/05/2019 08/27/2019
0.18 05/03/2019 04/23/2019 05/06/2019 05/28/2019
0.18 02/08/2019 01/30/2019 02/11/2019 03/04/2019
0.28 01/04/2019 12/21/2018 01/07/2019 01/29/2019
0.18 11/06/2018 10/23/2018 11/07/2018 11/27/2018
0.18 08/03/2018 07/24/2018 08/06/2018 08/28/2018
0.18 05/04/2018 04/24/2018 05/07/2018 05/30/2018
0.18 02/12/2018 01/31/2018 02/13/2018 03/06/2018
0.28 01/04/2018 12/21/2017 01/05/2018 01/29/2018
0.18 11/06/2017 10/24/2017 11/07/2017 11/27/2017
0.18 08/03/2017 07/25/2017 08/07/2017 08/29/2017
0.18 05/04/2017 04/26/2017 05/08/2017 05/30/2017
0.18 02/02/2017 01/25/2017 02/06/2017 02/27/2017
0.28 01/04/2017 12/23/2016 01/06/2017 01/30/2017
0.18 11/04/2016 10/25/2016 11/08/2016 11/28/2016
0.18 08/04/2016 07/28/2016 08/08/2016 08/29/2016
0.18 05/05/2016 04/28/2016 05/09/2016 05/30/2016
0.18 02/04/2016 01/28/2016 02/08/2016 02/29/2016
0.28 01/04/2016 12/23/2015 01/06/2016 01/26/2016
0.18 11/02/2015 10/26/2015 11/04/2015 11/25/2015
0.18 08/11/2015 07/23/2015 08/13/2015 09/04/2015
0.18 05/04/2015 04/27/2015 05/06/2015 05/28/2015
0.18 02/05/2015 01/29/2015 02/09/2015 02/23/2015
0.18 11/04/2014 10/22/2014 11/06/2014 11/26/2014
0.18 08/05/2014 07/23/2014 08/07/2014 08/28/2014
0.18 05/06/2014 04/22/2014 05/08/2014 05/29/2014
0.18 02/11/2014 01/30/2014 02/13/2014 02/28/2014
0.18 10/31/2013 10/24/2013 11/04/2013 11/26/2013
0.18 08/01/2013 07/23/2013 08/05/2013 08/27/2013
0.18 05/02/2013 04/23/2013 05/06/2013 05/28/2013
0.18 01/31/2013 01/23/2013 02/04/2013 02/22/2013
0.18 11/07/2012 10/31/2012 11/09/2012 11/28/2012
0.18 08/07/2012 07/24/2012 08/09/2012 08/30/2012
0.18 05/07/2012 04/27/2012 05/09/2012 05/31/2012
0.18 02/07/2012 01/26/2012 02/09/2012 03/01/2012
0.18 11/03/2011 10/28/2011 11/07/2011 11/28/2011
0.18 08/11/2011 08/08/2011 08/15/2011 09/06/2011
0.18 05/06/2011 04/29/2011 05/10/2011 06/01/2011
0.18 02/04/2011 01/28/2011 02/08/2011 03/01/2011
0.18 11/05/2010 11/02/2010 11/09/2010 12/01/2010
0.18 07/30/2010 07/27/2010 08/03/2010 08/23/2010
0.18 05/07/2010 05/04/2010 05/11/2010 06/01/2010
0.18 02/05/2010 01/29/2010 02/09/2010 03/02/2010
0.18 11/05/2009 10/30/2009 11/09/2009 11/30/2009
0.10 07/30/2009 07/23/2009 08/03/2009 08/21/2009
0.10 04/30/2009 04/24/2009 05/04/2009 05/22/2009
0.10 02/05/2009 01/28/2009 02/09/2009 02/27/2009
0.10 10/30/2008 10/24/2008 11/03/2008 11/21/2008
0.08 07/31/2008 07/24/2008 08/04/2008 08/22/2008
0.08 05/01/2008 04/24/2008 05/05/2008 05/23/2008
0.18 08/27/2004 08/20/2004 08/31/2004 09/17/2004
0.18 05/26/2004 05/13/2004 05/28/2004 06/18/2004
0.03 02/25/2004 02/17/2004 02/27/2004 03/19/2004
0.03 12/29/2003 12/10/2003 12/31/2003 01/16/2004
0.03 08/27/2003 08/18/2003 08/29/2003 09/19/2003
0.03 05/28/2003 05/12/2003 05/30/2003 06/20/2003
0.03 02/26/2003 02/12/2003 02/28/2003 03/21/2003
0.03 12/27/2002 12/18/2002 12/31/2002 01/17/2003
0.03 08/28/2002 08/15/2002 08/30/2002 09/20/2002
0.03 05/29/2002 05/15/2002 05/31/2002 06/21/2002
0.03 02/26/2002 02/18/2002 02/28/2002 03/22/2002
0.03 12/27/2001 12/24/2001 12/31/2001 01/18/2002
0.03 08/29/2001 08/14/2001 08/31/2001 09/21/2001
0.03 05/29/2001 05/16/2001 05/31/2001 06/22/2001
0.03 02/26/2001 02/12/2001 02/28/2001 03/23/2001
0.03 12/27/2000 12/19/2000 12/29/2000 01/12/2001
0.03 09/06/2000 08/30/2000 09/08/2000 09/22/2000
0.03 06/28/2000 06/19/2000 06/30/2000 07/21/2000
0.03 03/29/2000 03/21/2000 03/31/2000 04/21/2000
0.02 01/21/2000 11/30/-0001 11/30/-0001 11/30/-0001
0.02 12/29/1999 12/20/1999 12/31/1999 01/21/2000
0.02 09/29/1999 09/20/1999 10/01/1999 10/22/1999
0.02 06/30/1999 06/21/1999 07/02/1999 07/23/1999
a